GT200000200A - Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad. - Google Patents

Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad.

Info

Publication number
GT200000200A
GT200000200A GT200000200A GT200000200A GT200000200A GT 200000200 A GT200000200 A GT 200000200A GT 200000200 A GT200000200 A GT 200000200A GT 200000200 A GT200000200 A GT 200000200A GT 200000200 A GT200000200 A GT 200000200A
Authority
GT
Guatemala
Prior art keywords
cells
suppressors
diamino
immunity
compounds useful
Prior art date
Application number
GT200000200A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Eileen Elliot Mueller
Eric Jan Roskamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000200A publication Critical patent/GT200000200A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

EL INVENTO SE REFIERE A LA MODULACION TERAPEUTICA DE PROCESOS CELULARES MEDIADOS POR CELULAS T. LAS CELULAS T (CELULAS DERIVADAS DEL TIMO) SON RESPONSABLES DE NUMEROSAS FUNCIONES INMUNITARIAS MEDIADAS POR CELULAS, E INDIRECTAMENTE, POR ESTIMULACION DE CELULAS B, QUE CONTRIBUYEN A LA PRODUCCION DE ANTICUERPOS. LA MEMBRANA CELULAR DE UNA CELULA CONTIENE NUMEROSAS MOLECULAS DE RECEPTORES Y PROTEINAS ACCESORIAS QUE FACILITAN LA ACTIVACION DE CELULAS T, LA DIFERENCIACION DE CELULAS T EN DIVERSOS SUBTIPOS, Y LA INTERACCION CON OTRAS CELULAS O OTROS COMPONENTES DE CELULAS.
GT200000200A 1999-11-30 2000-11-29 Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad. GT200000200A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
GT200000200A true GT200000200A (es) 2002-05-23

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000200A GT200000200A (es) 1999-11-30 2000-11-29 Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad.

Country Status (33)

Country Link
EP (1) EP1242403B1 (es)
JP (1) JP3955468B2 (es)
KR (1) KR20020059826A (es)
CN (1) CN1402720A (es)
AP (1) AP2002002530A0 (es)
AT (1) ATE315036T1 (es)
AU (1) AU1047601A (es)
BG (1) BG106695A (es)
BR (1) BR0015995A (es)
CA (1) CA2392971C (es)
CO (1) CO5261519A1 (es)
CZ (1) CZ20021703A3 (es)
DE (1) DE60025385T2 (es)
EA (1) EA200200411A1 (es)
EE (1) EE200200275A (es)
ES (1) ES2253266T3 (es)
GT (1) GT200000200A (es)
HN (1) HN2000000264A (es)
HU (1) HUP0203300A3 (es)
IL (1) IL149103A0 (es)
IS (1) IS6339A (es)
MA (1) MA26846A1 (es)
MX (1) MXPA02005350A (es)
NO (1) NO20022557D0 (es)
OA (1) OA12097A (es)
PA (1) PA8506801A1 (es)
PE (1) PE20010900A1 (es)
PL (1) PL355946A1 (es)
SV (1) SV2002000231A (es)
TN (1) TNSN00232A1 (es)
TR (1) TR200201431T2 (es)
UY (1) UY26455A1 (es)
WO (1) WO2001040215A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
EA200300205A1 (ru) * 2000-08-31 2003-06-26 Пфайзер Продактс Инк. Производные пиразола и их применение в качестве ингибиторов протеинкиназы
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422377C (en) 2000-09-15 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
KR20050032105A (ko) 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 피라졸 조성물
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
KR20060133552A (ko) * 2004-01-16 2006-12-26 노파르티스 아게 2,4-디아미노피리미딘 및 심장근육발생 유도를 위한 그의용도
ATE512144T1 (de) * 2004-10-12 2011-06-15 Decode Genetics Ehf Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR20080095902A (ko) 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
AU2007227602A1 (en) * 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
BRPI0818338A2 (pt) * 2007-10-16 2015-04-22 Daiichi Sankyo Co Ltd Composto de pirimidil indolina
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
RU2012116525A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения перемидиновых производных, пригодных в качестве ингибиторов протеинкиназ
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
ES2930804T3 (es) 2017-06-30 2022-12-22 Beijing Tide Pharmaceutical Co Ltd Inhibidor de proteína cinasa asociada a RHO, composición farmacéutica que lo comprende, así como método de preparación y uso del mismo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE315036T1 (de) 2006-02-15
TR200201431T2 (tr) 2002-09-23
DE60025385T2 (de) 2006-08-24
PA8506801A1 (es) 2002-04-25
NO20022557L (no) 2002-05-29
AU1047601A (en) 2001-06-12
IL149103A0 (en) 2002-11-10
HUP0203300A3 (en) 2003-10-28
CN1402720A (zh) 2003-03-12
MXPA02005350A (es) 2002-12-11
OA12097A (en) 2006-05-04
BR0015995A (pt) 2002-08-06
DE60025385D1 (de) 2006-03-30
JP2003515602A (ja) 2003-05-07
AP2002002530A0 (en) 2002-06-30
WO2001040215A1 (en) 2001-06-07
KR20020059826A (ko) 2002-07-13
PL355946A1 (en) 2004-05-31
EP1242403A1 (en) 2002-09-25
NO20022557D0 (no) 2002-05-29
EA200200411A1 (ru) 2002-10-31
HUP0203300A2 (hu) 2003-02-28
HN2000000264A (es) 2001-05-21
PE20010900A1 (es) 2001-09-08
EE200200275A (et) 2003-10-15
MA26846A1 (fr) 2004-12-20
CA2392971C (en) 2008-10-07
ES2253266T3 (es) 2006-06-01
IS6339A (is) 2002-04-12
SV2002000231A (es) 2002-07-16
BG106695A (bg) 2002-12-29
CA2392971A1 (en) 2001-06-07
CZ20021703A3 (cs) 2003-06-18
UY26455A1 (es) 2001-07-31
JP3955468B2 (ja) 2007-08-08
CO5261519A1 (es) 2003-03-31
EP1242403B1 (en) 2006-01-04
TNSN00232A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
GT200000200A (es) Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad.
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
ATE365210T1 (de) Glykosylierte proteine mit reduzierter allergenität
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
CR7875A (es) Variantes de inmunoglobina y usos de esto
SV1997000071A (es) Serie de celulas inmortalizadas para el cultivo de virus
UY28276A1 (es) Ligandos de receptores de cannabinoides y sus usos
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
DE3787002T2 (de) Synthetische Peptide, die zelluläre Immunität gegen den AIDS-Virus und dessen Proteine erzeugen.
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
ECSP045382A (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
ATE271606T1 (de) Die aktivierung von rezeptoren durch gas6
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
BRPI0512235A (pt) polipeptìdeos ligadores de antìgenos e seus usos
CR7894A (es) Conjugados polimericos de interferon-beta con potencia biologica aumentada
ATE348632T1 (de) Prion protein peptide und deren verwendung
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
IN266744B (es)
ES2193192T3 (es) Receptores de interleuquina-15.
DE69702705T2 (de) Kondensierte pyrrolo(2,3-c) carbazole-6-one die die aktivität von gamma interferon potenzieren
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles